{"title":"Immunogenic Cell Death-relevant Molecular Patterns, Prognostic Genes, and Implications for Immunotherapy in Ovarian Cancer.","authors":"Pijun Gong, Jia Li, Yinbin Zhang, Shuqun Zhang","doi":"10.2174/0109298673354860250220065131","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OV) is one of the deadliest gynecologic cancers, and approximately 75% of serous ovarian cancer [SOC] patients are diagnosed at advanced stages due to the lack of effective biomarkers.</p><p><strong>Objective: </strong>Immunogenic cell death (ICD) has been investigated in many comprehensive studies, and the role of ICD in ovarian cancer and its impact on immunotherapy is not yet known.</p><p><strong>Method: </strong>The NMF clustering analysis was employed to categorize OV samples into different subgroups. Survival, mutation, and CNV analyses were performed in these clusters. ESTIMATE, CIBERSORT, TIDE, and drug sensitivity analyses [based on GDSC] were also performed on the subtypes. Then, differentially expressed immunogenic cell death genes (DE-ICDGs) in OV were obtained by crossing the DEGs between cluster 3 vs cluster 1, DEGs from the TCGA-GTEx dataset, and DEGs from the GSE40595 dataset. Functional enrichment analysis of DE-ICDGs was then performed. The signature genes related to the prognosis of OV in three OV datasets were excavated by drawing Kaplan-Meier curves. Finally, quantitative real-time PCR [qRT-PCR] was performed to verify the expression trends of the signature genes.</p><p><strong>Results: </strong>The NMF clustering analysis categorized OV samples into three distinct groups according to the expression levels of ICDGs, with differential analysis indicating that Cluster 3 represented the subgroup with high ICD expression. Mutation and CNV analysis did not differ significantly between clusters, but Amp and Del's numbers did. Immuno- infiltration analysis revealed that cluster 3 showed significant differences from cluster 1 and cluster 2. Immunotherapy and drug sensitivity analysis showed differences in immunotherapy and chemotherapy sensitivity between the clusters. The DEGs in cluster3 vs. cluster1, TCGA-GTEx dataset and GSE40595 dataset were intersected to obtain a total of 71 DE-ICDGs, and functional enrichment result suggested that the DE-ICDGs were significantly correlated with inflammatory response, complement system and positive regulation of cytokine production. 2 DE-ICDGs (FN1 and LUM) were identified that were associated with OV prognosis and were validated significantly down-regulated in the SOC group with PCR.</p><p><strong>Conclusion: </strong>We identified ICD-associated subtypes of OV and mined 2 OV prognostic genes (FN1 and LUM) associated with ICD, which may have important implications for OV prognosis and therapy.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673354860250220065131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Ovarian cancer (OV) is one of the deadliest gynecologic cancers, and approximately 75% of serous ovarian cancer [SOC] patients are diagnosed at advanced stages due to the lack of effective biomarkers.
Objective: Immunogenic cell death (ICD) has been investigated in many comprehensive studies, and the role of ICD in ovarian cancer and its impact on immunotherapy is not yet known.
Method: The NMF clustering analysis was employed to categorize OV samples into different subgroups. Survival, mutation, and CNV analyses were performed in these clusters. ESTIMATE, CIBERSORT, TIDE, and drug sensitivity analyses [based on GDSC] were also performed on the subtypes. Then, differentially expressed immunogenic cell death genes (DE-ICDGs) in OV were obtained by crossing the DEGs between cluster 3 vs cluster 1, DEGs from the TCGA-GTEx dataset, and DEGs from the GSE40595 dataset. Functional enrichment analysis of DE-ICDGs was then performed. The signature genes related to the prognosis of OV in three OV datasets were excavated by drawing Kaplan-Meier curves. Finally, quantitative real-time PCR [qRT-PCR] was performed to verify the expression trends of the signature genes.
Results: The NMF clustering analysis categorized OV samples into three distinct groups according to the expression levels of ICDGs, with differential analysis indicating that Cluster 3 represented the subgroup with high ICD expression. Mutation and CNV analysis did not differ significantly between clusters, but Amp and Del's numbers did. Immuno- infiltration analysis revealed that cluster 3 showed significant differences from cluster 1 and cluster 2. Immunotherapy and drug sensitivity analysis showed differences in immunotherapy and chemotherapy sensitivity between the clusters. The DEGs in cluster3 vs. cluster1, TCGA-GTEx dataset and GSE40595 dataset were intersected to obtain a total of 71 DE-ICDGs, and functional enrichment result suggested that the DE-ICDGs were significantly correlated with inflammatory response, complement system and positive regulation of cytokine production. 2 DE-ICDGs (FN1 and LUM) were identified that were associated with OV prognosis and were validated significantly down-regulated in the SOC group with PCR.
Conclusion: We identified ICD-associated subtypes of OV and mined 2 OV prognostic genes (FN1 and LUM) associated with ICD, which may have important implications for OV prognosis and therapy.
期刊介绍:
Aims & Scope
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.